Antiphospholipid antibodies and atherosclerosis

Eiji Matsuura, K. Kobayashi, T. Yasuda, T. Koike

Research output: Contribution to journalArticlepeer-review

33 Citations (Scopus)


β2-Glycoprotein I (β2-GPI) is a major antigen for anticardiolipin antibodies (aCL) induced in patients with antiphospholipid syndrome and their antigenic epitopes are cryptic. The epitopes appear on the surface of β2-GPI molecule only when β2-GPI interacts with lipid membranes containing negatively charged phospholipids or polyoxygenated polystyrene surface. Our data also indicated that CuSO4-oxidized low density lipoproteins (oxLDL) are subsequently targeted by β2-GPI and aCL; however, malonedialdehyde (MDA)-modified LDL were recognized neither by β2-GPI nor aCL. β2-GPI binding to LDL was rapidly increased by incubation with CuSO4. Oxidation of lipoproteins was accompanied with the increment of thiobarbituric acid-reactive substances (TBARS) and denature of apolipoprotein. Ligands on LDL for β2-GPI seemed to be intermediate oxidative derivatives which were extractable into the chloroform phase by Bligh and Dyer's extraction, but not MDA. Further, immune responses against β2-GPI, as an anti-atherogenic protein, were demonstrated to induce atherogenic effect in in vitro oxLDL uptake by macrophages.

Original languageEnglish
Pages (from-to)S135-S139
Issue numberSUPPL. 2
Publication statusPublished - 1998


  • Anticardiolipin antibodies
  • Atherosclerosis
  • Foam cell
  • Oxidized LDL
  • β-glycoprotein I

ASJC Scopus subject areas

  • Rheumatology


Dive into the research topics of 'Antiphospholipid antibodies and atherosclerosis'. Together they form a unique fingerprint.

Cite this